.Attribute Medicine, Released online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized period 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) procedure of clients with HER2+ advanced bosom cancer and energetic or stable mind metastases showed regular intracranial activity as well as wide spread efficacy of T-DXd.